Trombovazim capsules 400 units, 50 pcs.

Fibrinolytic agent.

It has thrombolytic, anti-inflammatory and cardioprotective effects.

The mechanism of thrombolytic action is associated with direct destruction of fibrin filaments which form the main carcass of the thrombus. Mechanism of anti-inflammatory action is connected with influence on oxidative function of blood neutrophils and tissue macrophages. Mechanism of cardioprotective action is connected with the improvement of myocardial blood supply.

Trombovasim^® is a low-toxic drug.

Trombovasim^® does not lower platelet levels and does not affect clotting time or bleeding duration.

Indications

As an adjuvant in complex therapy of chronic venous insufficiency.

Pharmacological effect

Fibrinolytic agent.

It has thrombolytic, anti-inflammatory and cardioprotective effects.

The mechanism of thrombolytic action is associated with the direct destruction of fibrin threads that form the main framework of the thrombus. The mechanism of anti-inflammatory action is associated with the effect on the oxidative function of blood neutrophils and tissue macrophages. The mechanism of cardioprotective action is associated with improved blood supply to the myocardium.

Trombovazim® is a low-toxic drug.

Thrombovazim® does not reduce platelet levels and does not affect clotting time or bleeding duration.

Special instructions

Impact on the ability to drive vehicles and operate machinery

Studies on the possible effect of the drug on the ability to drive vehicles and machinery have not been conducted, because the drug and its components are not substances that can affect the psychomotor state of a person.

Active ingredient

Thrombovazim

Composition

1 caps. – a complex of proteinases produced by Bacillus subtilis, immobilized by radiation on macrogol 1500 with the addition of dextran (Trombovazim) 400 units.

Pregnancy

The drug is contraindicated for use during pregnancy and lactation (breastfeeding).

Contraindications

– peptic ulcer of the stomach and duodenum in the acute phase;

– pregnancy;

– lactation;

– age under 18 years (efficacy and safety have not been established);

– simultaneous use with drugs containing salts of divalent metals (calcium, magnesium, zinc, iron) and tetracycline antibiotics (tetracycline, chlortetracycline hydrochloride and oxytetracycline hydrochloride);

– hypersensitivity to the components of the drug.

The drug should be used with caution in patients with polyvalent allergies, COPD, with the threat of bleeding from the veins of the esophagus, urolithiasis, and with gastric and duodenal ulcers in remission.

Side Effects

From the digestive system: rarely – dyspeptic symptoms (nausea, vomiting, feeling of heaviness in the stomach).

Other: possible – allergic reactions, temporary feeling of fullness in the lower extremities.

Interaction

Heparin, dipyridamole, acetylsalicylic acid enhances the antithrombotic effect without increasing the risk of bleeding.

Use with tetracycline antibiotics (tetracycline, chlortetracycline hydrochloride and oxytetracycline hydrochloride) enhances the effect of fibrinolytics.

If it is necessary to use drugs containing salts of divalent metals (calcium, magnesium, zinc, iron) due to a possible decrease in enzyme activity, it is advisable to maintain an interval between doses of Trombovazim® and these drugs for at least 40 minutes.

Overdose

There were no cases of overdose of the drug Trombovazim®.

Recommendations for use

Take orally 30-40 minutes before meals at a dose of 800-1600 units per day in 2 divided doses.

Storage conditions

The drug should be stored out of the reach of children, in a dry place, protected from light, at a temperature not exceeding 25°C.

Shelf life

2 years

Manufacturer

SCFB, Russia